Key autoantigens in SLE

Rheumatology

Volumn 44, Issue 8, 2005, Pages 975-982

  Riemekasten, Gabriela ^b   Hahn, B H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; CELL NUCLEUS ANTIGEN; DNA ANTIBODY; DOUBLE STRANDED DNA; EPSTEIN BARR VIRUS ANTIGEN; PHOSPHOLIPID ANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN;

ANTIGEN DETECTION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MOLECULAR MIMICRY; NONHUMAN; NUCLEOSOME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIRUS INFECTION; BIOSYNTHESIS; IMMUNOLOGY; REVIEW; T LYMPHOCYTE SUBPOPULATION;

APOPTOSIS; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS;

EID: 24944487278     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh688     Document Type: Conference Paper

References (105)

1. Mason LJ, Isenberg DA. Immunopathogenesis of SLE. Baillieres Clin Rheumatol 1998;12:385-403.
2. Holyst MM, Hill DL, Hoch SO, Hoffman RW. Analysis of human T cell and B cell responses against U small nuclear ribonucleoprotein 70-kd, B, and D polypeptides among patients with systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 1997;40:1493-503.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
4. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A. Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis 1998;32:825-8.
5. Verdolini R, Bugatti L, Giangiacomi M, Nicolini M, Filosa G, Cerio R. Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 2002;146:877-81.
6. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-6.
7. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-26.
8. Moon UY, Park SJ, Oh ST et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004;6:R295-R302.
9. Sundar K, Jacques S, Gottlieb P et al. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun 2004;23:127-40.
10. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/ B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-61.
11. James JA, Scofield RH, Harley JB. Lupus humoral autoimmunity after short peptide immunization. Ann N Y Acad Sci 1997;815: 124-7.
12. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol 2002;168:2054-62.
13. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998;16:289-94.
14. Marchini B, Dolcher MP, Sabbatini A, Klein G, Migliorini P. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases. J Autoimmun 1994;7:179-91.
15. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11:85-9.
16. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
17. Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS. Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol 1989; 142:1482-6.
18. Krieg AM. CpG DNA: A pathogenic factor in systemic lupus erythematosus? J Clin Immumol 1995;15:284-92.
19. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 1996;157:4918-25.
20. Marshak-Rothstein A, Busconi L, Rifkin IR, Viglianti GA. The stimulation of Toll-like receptors by nuclear antigens: A link between apoptosis and autoimmunity. Rheum Dis Clin North Am 2004; 30:559-74.
21. Bing H, Xugang Q, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173:4479-91.
22. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
23. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
24. Crozat K, Beutler B. TLR7: A new sensor of viral infection. Proc Natl Acad Sci USA 2004;101:6835-6.
25. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004;199:1631-40.
26. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
27. Riemekasten G, Langnickel D, Ebling FM et al. Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum 2003;48:475-85.
28. Sharma A, Isenberg DA, Diamond B. Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: Clues to their origin. J Autoimmun 2001;16:479-84.
29. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005; 25:29-40.
30. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005;174:2429-34.
31. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004;18:534-6.
32. Hasegawa K, Hayashi T. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus 2003;12:838-45.
33. Gilkeson GS, Ruiz P, Pippen AM, Alexander AL, Lefkowith JB, Pisetsky DS. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med 1996; 183:1389-97.
34. Shlomshik M. How do autoantibody responses evolve. 6th European Lupus Meeting, March 2005, oral presentation.
35. Hur JW, Shin HD, Park BL, Kim LH, Kim SY, Bae SC. Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens 2005;65:266-70.
36. Hahn BH. Antibodies to DNA. N Engl J Med 1998:338:1359-68.
37. Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: Immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 1993;69:494-507.
38. Takeda I, Rayno K, Movafagh FB, Wolfson -Reichlin M, Reichlin M. Dual binding capabilities of anti-double-stranded DNA antibodies and anti-ribosomal phosphoprotein (P) antibodies. Lupus 2001;10:857-65.
39. Lefkowith JB, Kiehl M, Rubenstein J et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996;98:1373-80.
40. Deocharan B, Qing X, Beger E, Putterman C. Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. Lupus 2002;11:865-71.
41. Zieve GW, Khusial PR. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun Rev 2003;2:235-40.
42. Desai DD, Krishnan MR, Swindle JT, Marion TN. Antigen-specific induction of antibodies against native mammalian DNA in nonautoimmune mice. J Immunol 19931;151:1614-26.
43. Putterman C, Diamond B. Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J Exp Med 1998;188:29-38.
44. Gabler C, Kalden JR, Lorenz HM. The putative role of apoptosis-modified histories for the induction of autoimmunity in systemic lupus erythematosus. Biochem Pharmacol 2003;66:1441-6.
45. Koutouzov S, Jeronimo AL, Campos H, Amoura Z. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004;30:529-58, ix.
46. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
47. Jovelin F, Mostoslavsky G, Amoura Z et al. Early anti-nucleosome autoantibodies from a single MRL+/+ mouse: Fine specificity, V gene structure and pathogenicity. Eur J Immunol 1998;28:3411-22.
48. Mackay IR, Rowley MJ. Autoimmune epitopes: Autoepitopes. Autoimmun Rev 2004;3:487-92.
49. Hoch SO, Eisenberg RA, Sharp GC. Diverse antibody recognition patterns of the multiple Sm-D antigen polypeptides. Clin Immunol 1999;92:203-8.
50. James JA, Mamula MJ, Harley JB. Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies. Clin Exp Immunol 1994;98:419-26.
51. Mahler M, Fritzler MJ, Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther 2005;7:R19-29.
52. Riemekasten G, Marell J, Trebeljahr G et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998;102:754-63.
53. Tsao BP, Grossman JM, Riemekasten G et al. Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002;46:2678-85.
54. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-15.
55. Jaekel HP, Klopsch T, Benkenstein B et al. Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. J Autoimmun 2001;17:347-54.
56. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J Exp Med 1999; 190:815-26.
57. Gensler TJ, Hottelet M, Zhang C, Schlossman S, Anderson P, Utz PJ. Monoclonal antibodies derived from BALB/c mice immunized with apoptotic Jurkat T cells recognize known autoantigens. J Autoimmun 2001;16:59-69.
58. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-92.
59. Malmegrim KC, Pruijn GJ, van Venrooij WJ. The fate of the U1 snRNP autoantigen during apoptosis: Implications for systemic autoimmunity. Isr Med Assoc J 2002;4:706-12.
60. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
61. Mitchell DA, Pickering MC, Warne J et al. C1q deficiency and autoimmunity: The effects of genetic background on disease expression. J Immunol 2002;168:2538-43.
62. Kim SJ, Gershov D, Ma X, Brot N, Elkon KB. Opsonization of apoptotoic cells and its effect on macrophage and T cell immune responses. Ann N Y Acad Sci 2003;987:68-78.
63. Sekigawa I, Naito T, Hira K et al. Possible mechanisms of gender bias in SLE: A new hypothesis involving a comparison of SLE with atopy. Lupus 2004;13:217-22.
64. McMurray RW, Suwannaroj S, Ndebele K, Jenkins JK. Differential effects of sex steroids on T and B cells: Modulation of cell cycle phase distribution, apoptosis and bcl-2 protein levels. Pathobiology 2001;69:44-58.
65. Nakamura N, Ban T, Yamaji K, Yoneda Y, Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998;101:1951-9.
66. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med 1995; 181:1557-61.
67. Andreassen K, Bendiksen S, Kjeldsen E et al. T cell autoimmunity to histones and nucleosomes is a latent property of the normal immune system. Arthritis Rheum 2002;46:1270-81.
68. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996;183:2459-69.
69. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999;104:345-55.
70. Monneaux F, Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev 2004;3:16-24.
71. Riemekasten G, Weiss C, Schneider S et al. T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:779-85.
72. Singh RR, Hahn BH, Tsao BP, Ebling FM. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J Clin Invest 1998;102:1841-9.
73. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002;1:329-37.
74. Adams S, Leblanc P, Datta SK. Junctional region sequences of T-cell receptor beta-chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: Possible selection by cationic autoantigens. Proc Natl Acad Sci USA 1991;88:11271-5.
75. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
76. Deshmukh US, Gaskin F, Lewis JE, Kannapell CC, Fu SM. Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann N Y Acad Sci 2003;987:91-8.
77. Haley J, Mason LJ, Nagl S el al. Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Mol Immunol 2004;40: 745-58.
78. Singh RR, Kumar V, Ebling FM et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 1995;181:2017-27.
79. Eilat E, Dayan M, Zinger H, Mozes E. The mechanisms by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA autoAb ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001;98:1148-53.
80. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells, and upon subsequent immunization induce their immune deviation: Implications for antibody-vs T cell-mediated autoimmunity. J Exp Med 1996;183:1613-22.
81. Hahn BH, Singh RR, Wong WK, Bulpitt K, Tsao BP, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44:432-41.
82. Kalsi JK, Grossman J, Kim JM et al. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Relation of cytokine pattern to disease duration. Lupus 2004;13:490-500.
83. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of SLE patients. Clin Exp Immunol 2004;137:513-20.
84. Riemekasten G, Langnickel D, Enghard P et al. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004; 173:5835-41
85. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003;33:287-96.
86. Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999;162:5775-83.
87. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004;137:513-20.
88. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
89. Datta SK. Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann N Y Acad Sci 2003;987:79-90.
90. Flaegstad T, Fredriksen K, Dahl B, Traavik T, Rekvig OP. Inoculation with BK virus may break immunological tolerance to histone and DNA antigens. Proc Natl Acad Sci USA 1988;85:8171-5.
91. Gonzalez CM, Lopez-Longo FJ, Monteagudo I et al. Antiribonucleoprotein antibodies in children with human immuno-deficiency virus infection: comparative study with childhood-onset systemic lupus erythematosus. Pediatr AIDS HIV Infect 1996;7: 401-8.
92. Daikh BE, Holyst MM. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: Case report and literature review. Semin Arthritis Rheum 2001;30:418-25.
93. De Keyser F, Hoch SO, Takei M et al. Cross-reactivity of the B/B′ subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides. Clin Immunol Immunopathol 1992;62:285-90.
94. Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, Bluthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med 2003;81:194-204.
95. Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H. Anti-telomere antibodies in systemic lupus erythematosus (SLE): A comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Ann Rheum Dis 2004;63:1250-4.
96. Schett G, Smole J, Zimmermann C et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: Autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 2002; 11:704-15.
97. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 2004; 43:220-4.
98. Benito-Garcia E, Schur PH, Lahita R, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004;51:1030-44.
99. Mahler M, Stinton LM, Fritzler MJ. Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 2005;12:107-13.
100. Ghirardello A, Doria A, Zampieri S et al. Detection of serum anti-B/B′ UsnRNP antibodies in patients with connective tissue diseases by immunoblotting. Reumatismo 2002;54:324-30.
101. Riemekasten G, Kawald A, Weiss C et al. Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. Arthritis Rheum 2001;44:2435-45.
102. Reynolds P, Gordon TP, Purcell AW, Jackson DC, McCluskey J. Hierarchical self-tolerance to T cell determinants within the ubiquitous nuclear self-antigen La (SS-B) permits induction of systemic autoimmunity in normal mice. J Exp Med 1996;184: 1857-70.
103. Dumortier H, Monneaux F, Jahn-Schmid B et al. B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol 2000;165:2297-305.
104. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
105. Ravirajan CT, Muller S, Katz DR, Isenberg DA. Effect of histone and histone-RNA complexes on the disease process of murine systemic lupus erythematosus. Autoimmunity 1995; 21:117-22.